Lista de obras -

AR Signaling in Breast Cancer

scientific article published on 24 February 2017

Adjuvant anthracyclines: time for a change of heart?

artículo científico publicado el 1 de febrero de 2011

Adjuvant hormonal therapy for early-stage breast cancer

artículo científico publicado en 2008

African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages

artículo científico publicado en 2017

Analysis of tumor template from multiple compartments in a blood sample provides complementary access to peripheral tumor biomarkers

artículo científico publicado en 2016

Benchmarks for Academic Oncology Faculty

scientific article published on 30 September 2020

Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

artículo científico publicado en 2016

Biomedical nanotechnology for molecular imaging, profiling, and drug targeting

artículo científico publicado en 2005

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

artículo científico publicado en 2017

Characteristics and treatment modalities for African American women diagnosed with stage III breast cancer

scientific article published on July 2009

Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer

artículo científico publicado en 2019

Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).

artículo científico publicado en 2014

Determining the impact of US mammography screening guidelines on patient survival in a predominantly African American population treated in a public hospital during 2008.

artículo científico

Dual-targeting Wnt and uPA receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer

artículo científico publicado en 2017

ER+/HER2+ Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER-/HER2+ Breast Cancer

artículo científico publicado en 2019

Emerging nontaxane therapies for metastatic breast cancer

artículo científico publicado el 1 de marzo de 2012

Endocrine therapy for the treatment of postmenopausal women with breast cancer

artículo científico publicado en 2009

Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies

artículo científico publicado en 2020

Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score.

artículo científico publicado en 2017

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

artículo científico publicado en 2014

Everolimus: side effect profile and management of toxicities in breast cancer

artículo científico publicado en 2013

FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells

artículo científico publicado en 2015

Hormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients

artículo científico publicado en 2017

Implementation of a chemotherapy stewardship process

artículo científico publicado en 2020

Improving on national quality indicators of breast cancer care in a large public hospital as a means to decrease disparities for African American women

artículo científico publicado en 2010

Inorganic nanoparticles for predictive oncology of breast cancer

scientific article published on January 2009

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

artículo científico publicado en 2020

Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients

artículo científico publicado en 2014

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.

artículo científico publicado en 2016

Molecular Assays to Determine Optimal Duration of Adjuvant Endocrine Therapy in Breast Cancer

scientific article published on 15 August 2020

Neoadjuvant Hormonal Therapy is Associated with Comparable Outcomes to Neoadjuvant Chemotherapy in Post-Menopausal Women with Estrogen Receptor-Positive Breast Cancer

artículo científico publicado en 2013

New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus

artículo científico publicado en 2013

Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab ⬇️

artículo científico publicado el 25 de octubre de 2010

Progress in breast cancer research amid the COVID-19 gloom

artículo científico publicado en 2020

Quantum dots for human mesenchymal stem cells labeling. A size-dependent autophagy activation

artículo científico publicado en 2006

Race, breast cancer, and prognosis: Where biology is queen?

scientific article published on 17 June 2019

Review: bisphosphonates prevent or delay skeletal events in women with advanced breast cancer and bone metastases.

artículo científico publicado en 2006

Right atrial and ventricular thrombus infiltrated with osteoblastic osteosarcoma.

artículo científico publicado en 2003

Role of the androgen receptor in triple-negative breast cancer

scientific article published on March 2016

Selection of optimal adjuvant endocrine therapy for early-stage breast cancer

artículo científico publicado en 2006

Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.

artículo científico publicado en 2012

The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy

artículo científico publicado en 2012

The Impact of Skin-Sparing Mastectomy With Immediate Reconstruction in Patients With Stage III Breast Cancer Treated With Neoadjuvant Chemotherapy and Postmastectomy Radiation ⬇️

artículo científico publicado el 22 de diciembre de 2011

The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers

artículo científico publicado en 2014

The emerging role of mediator complex subunit 12 in tumorigenesis and response to chemotherapeutics

artículo científico publicado en 2019

Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies

scientific article published on 19 May 2020

Treatment adherence and outcome in women with inflammatory breast cancer: does race matter?

artículo científico publicado en 2011

Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer

artículo científico publicado en 2016

Triple-negative breast cancer in African-American women: disparities versus biology

artículo científico publicado en 2015

Using National Quality Forum breast cancer indicators to measure quality of care for patients in an AVON comprehensive breast center

artículo científico publicado en 2010

mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy ⬇️

artículo científico publicado el 8 de abril de 2011

Lista de obras de

AR Signaling in Breast Cancer

Adjuvant anthracyclines: time for a change of heart?

Adjuvant hormonal therapy for early-stage breast cancer

African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages

Analysis of tumor template from multiple compartments in a blood sample provides complementary access to peripheral tumor biomarkers

Benchmarks for Academic Oncology Faculty

Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

Biomedical nanotechnology for molecular imaging, profiling, and drug targeting

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

Characteristics and treatment modalities for African American women diagnosed with stage III breast cancer

Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer

Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).

Determining the impact of US mammography screening guidelines on patient survival in a predominantly African American population treated in a public hospital during 2008.

Dual-targeting Wnt and uPA receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer

ER+/HER2+ Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER-/HER2+ Breast Cancer

Emerging nontaxane therapies for metastatic breast cancer

Endocrine therapy for the treatment of postmenopausal women with breast cancer

Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies

Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score.

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

Everolimus: side effect profile and management of toxicities in breast cancer

FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells

Hormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients

Implementation of a chemotherapy stewardship process

Improving on national quality indicators of breast cancer care in a large public hospital as a means to decrease disparities for African American women

Inorganic nanoparticles for predictive oncology of breast cancer

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.

Molecular Assays to Determine Optimal Duration of Adjuvant Endocrine Therapy in Breast Cancer

Neoadjuvant Hormonal Therapy is Associated with Comparable Outcomes to Neoadjuvant Chemotherapy in Post-Menopausal Women with Estrogen Receptor-Positive Breast Cancer

New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus

Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab ⬇️

Progress in breast cancer research amid the COVID-19 gloom

Quantum dots for human mesenchymal stem cells labeling. A size-dependent autophagy activation

Race, breast cancer, and prognosis: Where biology is queen?

Review: bisphosphonates prevent or delay skeletal events in women with advanced breast cancer and bone metastases.

Right atrial and ventricular thrombus infiltrated with osteoblastic osteosarcoma.

Role of the androgen receptor in triple-negative breast cancer

Selection of optimal adjuvant endocrine therapy for early-stage breast cancer

Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.

The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy

The Impact of Skin-Sparing Mastectomy With Immediate Reconstruction in Patients With Stage III Breast Cancer Treated With Neoadjuvant Chemotherapy and Postmastectomy Radiation ⬇️

The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers

The emerging role of mediator complex subunit 12 in tumorigenesis and response to chemotherapeutics

Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies

Treatment adherence and outcome in women with inflammatory breast cancer: does race matter?

Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer

Triple-negative breast cancer in African-American women: disparities versus biology

Using National Quality Forum breast cancer indicators to measure quality of care for patients in an AVON comprehensive breast center

mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy ⬇️